ScholarWorks@Korea University College of Medicine: Choi, Won Suk

Detailed Information

Choi, Won Suk (최원석)

Ansan Hospital (Department of Infectious Diseases, Ansan Hospital)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

COVID19:21||Influenza:17||SARSCoV2:12||Korea:9||Safety:9||Immunogenicity:7||Vaccination:7||Republic of Korea:7||Vaccine:7||Vaccines:5||Effectiveness:5||Epidemiology:5||Herpes zoster:5||influenza vaccine:4||Risk factors:4||Acinetobacter baumannii:4||Guideline:3||immunogenicity:3||Human:3||influenza:3||influenza vaccines:3||2009 H1N1:3||Immunization:3||Bacteremia:3||Adult:3||Pneumococcal infections:3||Streptococcus pneumoniae:3||Surveillance:3||Pneumonia:3||Policy:3||herpes zoster:3||bacteremia:2||pneumonia:2||COVID19 vaccination:2||Casecontrol study:2||quadrivalent influenza vaccine:2||인플루엔자:2||H1N1:2||Antiviral:2||Olfaction Disorders:2||Sepsis:2||Incidence:2||septic shock:2||Diabetes mellitus:2||Serotype:2||Infection Control:2||Escherichia coli:2||Middle East respiratory syndrome:2||Pregnancy:2||Mortality:2||influenza A virus:2||Tuberculosis:2||지침:2||Influenza vaccines:2||Diagnosis:2||Childbearing age:2||Pneumococcus:2||vaccine:2||effectiveness:2||vaccine effectiveness:2||elderly:2||epidemiology:2||hospitalization:2||Fever of unknown origin:2||human:2||Nanoparticle vaccine:2||Autoimmune inflammatory rheumatic disease:2||ChAdOx1:2||Treatment:2||Hospitalization:2||Recombinant protein vaccine:2||mortality:2||Communityacquired pneumonia:2||Influenza vaccine:2||Practice guideline:2||Perception:2||Pandemic:2||pandemic:2||BNT162b2:2||Hantavirus:1||Health Personnel:1||Health care workers:1||Health surveys:1||Healthcare delay:1||Healthcare personnel:1||Hepatitis A virus:1||Hepatitis B virus:1||Herpes Zoster Vaccine:1||Herpes zoster vaccine:1||Herpesvirus 3:1||Heterologous vaccination:1||High dose influenza vaccine:1||Histoplasma capsulatum:1||Hospitalized:1||Humans:1||Humoral:1||Humoral immunity:1||Hypersensitivity pneumonitis:1||ICU:1||IFNγ:1||IgG:1||Immunity:1||Immunocompromised conditions:1||Immunology:1||Imnnumocompromised host:1||Inactivated:1||Inactivated quadrivalent influenza vaccine:1||Infected aortic aneurysm:1||Infection control:1||Influenza A:1||Influenza A virus:1||Influenza B:1||Influenza B virus:1||Influenza Vaccines:1||Influenza vaccination:1||Influenzalike Illness:1||Interleukin6:1||Intradermal injection:1||Intradermal injections:1||Intramuscular injection:1||Invasive pneumococcal disease:1||JarischHerxheimer reaction:1||Lactococcus lactis:1||Linked database:1||Liver Abscess:1||Liver Cirrhosis:1||Lupus nephritis:1||MERS:1||MF59:1||MF59 adjuvant:1||MF59 oil emulsion:1||MHC class I multimer:1||Maternal Welfare:1||Measles:1||Measles (rubeola):1||MeaslesMumpsRubella Vaccine:1||Memory T cell:1||Monitoring:1||Multilocus Sequence Typing:1||Multidetector computed tomography:1||Mycobacterium abscessus:1||Mycobacterium fortuitum:1||Neuralgia:1||Neutralization tests:1||Nocardiosis:1||NonNIP:1||Novel coronavirus disease 2019 (COVID19):1||Observational:1||Obstructive:1||Occupational exposure:1||Older adults:1||Omicron breakthrough infection:1||Outbreak:1||PCV13:1||PD1:1||PPSV23:1||Pain:1||Pandemics:1||Pentraxin 3:1||Peramivir:1||Periodic fever:1||Personal protective equipment:1||Pertussis:1||Pertussis Seroprevalence:1||Physician:1||Piperacillin:1||Pneumococcal Conjugate Vaccine:1||Pneumococcal Infections:1||Pneumococcal Pneumonia:1||Pneumococcal Polysaccharide Vaccine:1||Pneumococcal Vaccines:1||Pneumococcal conjugate vaccine:1||Pneumococcal infection:1||Pneumococcal pneumonia:1||Pneumococcal vaccines:1||Pointofcare systems:1||Population pharmacokinetics:1||Population surveillance:1||Populationbased cohort:1||Postexposure prophylaxis:1||Prediabetic state:1||Prednisolone:1||Pregnant Women:1||Prevention of herpes zoster:1||Procalcitonin:1||Prognosis:1||Psoas muscle:1||Pulmonary:1||Pyelonephritis:1||QIV:1||Quality of life:1||Race:1||Raoultella planticola:1||Reactogenicity:1||Residual lymph node:1||Respiratory syncytial virus:1||Respiratory tract pathogens:1||Review:1||SARSCoV2 Omicron Variant:1||SARSCoV2 infection:1||SARSCoV2 variants:1||Scrub typhus:1||Sentinel surveillance:1||Septic shock:1||Seroprevalence:1||Sleep Apnea:1||South Korea:1||Spondylitis:1||Spondylodiscitis:1||Standard dose influenza vaccine:1||Staphylococcus aureus:1||Streptococcus:1||Survey:1||Symptom:1||Syphilis:1||TIV:1||Taste Disorders:1||Tazobactam:1||Tdap:1||Therapeutics:1||Transmission:1||Treatment outcomes:1||Tsutsugamushi:1||Tuberculous lymphadenitis:1||Urinary tract infection:1||Urinary tract infections:1||VPD:1||Vaccine Efficacy:1||Vaccine effectiveness:1||Vaccine immunogenicity:1||Vancomycin resistance:1||Varicella zoster virus:1||Varicellazoster virus:1||Voriconazole:1||Yersinia:1||Yersinia infections:1||Yersinia pseudotuberculosis:1||adjuvant system:1||adult:1||adult vaccination:1||adult vaccines:1||adults:1||antibiotics:1||antigen imprinting:1||antiviral agents:1||aortic arch:1||binding assays:1||blade:1||blood transfusion:1||breakthrough infection:1||cardiopulmonary disease:1||catheterrelated infections:1||cell culture techniques:1||chest Xray:1||ciclesonide:1||clinical trial:1||combination therapy:1||communityacquired pneumonia:1||contamination:1||convolutional neural network:1||coronavirus:1||coronavirus disease:1||correlation:1||costeffectiveness:1||cutaneous infection:1||deep learning:1||diagnosis:1||disease burden:1||extended care facilities:1||extraction:1||gE subunit vaccine:1||geometric mean titer:1||geometric mean titer ratio:1||health education:1||hepatitis:1||herpes zoster vaccine:1||heterologous booster vaccination:1||hospital mortality:1||hospitalbased influenza morbidity and mortality (HIMM):1||human Influenza:1||immunity:1||immunoassay:1||immunocompromised host:1||inactivated:1||inactivated influenza vaccine:1||infected aneurysm:1||influenza B virus:1||influenzalike illness:1||inhalation:1||invasive ExPEC disease:1||isolation:1||lot consistency:1||lysis:1||mRNA Vaccine:1||mRNA vaccines:1||magnetic beads:1||moxifloxacin:1||neutralization tests:1||neutralizing antibodies:1||neutralizing antibody:1||nucleic acid:1||older adults:1||outcome:1||pneumococcal vaccination:1||pneumococcal vaccine:1||procalcitonin:1||protective immunity:1||renal dialysis:1||resistance:1||sVNT:1||safety:1||sensitivity:1||sepsis:1||sequential vaccination:1||seroprevalence:1||severe sepsis:1||specificity:1||stewardship:1||strategy:1||substitution:1||surveillance:1||targeted literature review:1||transmission:1||trivalent influenza vaccine:1||type 2 diabetes:1||vaccination:1||vaccination (immunization):1||vaccine preventable diseases:1||vaccinepreventable diseases:1||varicella:1||varicella zoster virus:1||varicellazoster virus:1||victoria lineage:1||virus:1||vitamin D:1||vitamin D deficiency:1||yamagata lineage:1||감염관리:1||경막외농양:1||스테로이드:1||중증:1||척수 골수염:1||체외막 산소공급:1||치료:1||.:1||항바이러스제:1||23valent pneumococcal vaccine:1||Abacavir:1||Acinetobacter infections:1||Adult patient:1||Adverse Effects:1||Adverse Event:1||Aged:1||Ageusia:1||Alzheimer:1||Amikacin:1||Anosmia:1||AntiSARSCoV2 monoclonal antibody:1||Antiretroviral:1||Antibacterial agents:1||Antibiotic susceptibility:1||Antibody affinity:1||Antigenic determinants:1||Antituberculous treatment:1||Antiviral agents:1||Asia Pacific:1||Asymptomatic infection:1||Attenuated vaccine:1||Autoimmune diseases:1||Awareness:1||Bacteriuria:1||Burden of illness:1||Creactive protein:1||CD8+ T cell:1||COVID19 vaccine:1||Campylobacter:1||Candida:1||Cefditoren:1||Cell culture techniques:1||Cellular immunity:1||Cervical tuberculous lymphadenitis:1||Chemoprophylaxis:1||Cholangitis:1||Chronic cardiovascular disease:1||Chronic respiratory disease:1||Chylothorax:1||Chylous ascites:1||Clearance:1||Clinical Trial:1||Clinical practice guidelines:1||Clinical trial:1||Clostridium septicum:1||Cofomulate of lamivudine:1||Colon cancer:1||Combination drug therapy:1||Community treatment center:1||CommunityAcquired Pneumonia:1||Complication:1||Complications:1||Cost of illness:1||Dementia:1||Digital health care monitoring system:1||Disease Outbreaks:1||Disease burden:1||Distribution:1||Drug resistance:1||Duration of treatment:1||EMA:1||Elderly:1||Emergency department:1||Empyema:1||Emulsion adjuvant:1||Enhanced environmental cleaning:1||Enterococcus:1||Epidural abscess:1||European Medicines Agency:1||Extrapulmonary tuberculousis:1||Fungemia:1||GMT:1||GMTR:1||GradCAM:1||H5N1:1||H7N9 Virus:1||Hantaan virus:1||

STATISTICS: Total View :12,772,433; Today View :3,894

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE